Physician profile
Stuart M Homer
NPI 1760488373
$4,410.71
in general payments reported to CMS, 2019-2025
39 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $515 · 2021: $534 · 2022: $691 · 2023: $708 · 2024: $712 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.55 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $402.16 | 2021-2025 | |
| Novo Nordisk INC | $349.15 | 2019-2025 | Wegovy, Ozempic |
| Fresenius USA Marketing, INC. | $258.62 | 2019-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.80 | 2019-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $182.61 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $176.26 | 2021-2025 | Veltassa, Korsuva |
| Amgen INC. | $159.96 | 2020-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $145.13 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $136.42 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $131.16 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $118.57 | 2021-2024 | Lupkynis |
| Baxter Healthcare | $117.87 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Ardelyx, INC. | $110.97 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $105.63 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $98.91 | 2023-2024 | Benlysta, Jesduvroq |
| Merck Sharp & Dohme LLC | $96.95 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $96.33 | 2022-2024 | Tarpeyo |
| Nxstage Medical, INC. | $94.71 | 2025 | Nxstage Cartridge Express, Nxstage System One, Pureflow Sl |
| Travere Therapeutics, INC. | $92.78 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.84 | 2022-2025 | Xifaxan, Trulance |
| Mallinckrodt Hospital Products INC. | $69.32 | 2022-2025 | Acthar |
| Lilly USA, LLC | $67.71 | 2019-2025 | Jardiance |
| Akebia Therapeutics INC | $66.47 | 2019-2025 | Vafseo |
| Amarin Pharma, INC. | $41.40 | 2020 | |
| Mallinckrodt Enterprises LLC | $38.90 | 2019 | |
| Abbott Laboratories | $38.88 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $38.61 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $28.93 | 2020 | |
| Scpharmaceuticals INC. | $20.83 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.98 | 2024 | Edarbyclor |
| Dexcom, INC. | $17.00 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $15.55 | 2025 | Cologuard Collection Kit |
| Fresenius USA Manufacturing, INC. | $15.04 | 2023 | Korsuva, Velphoro |
| Alexion Pharmaceuticals, INC. | $15.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.58 | 2019 | |
| Abbvie INC. | $13.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Homer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.